Join this Webinar to better understand contemporary practices for data generation strategies; describe how to design data generation strategies, implementation of the strategies, and how to communicate new evidence; and describe how real-world evidence may be utilized to support product value including regulatory label change.
In this session, you will hear “insider tips” from three senior-level Medical Affairs leaders from leading multinational biopharma companies.
This MAPS podcast introduces listeners to social listening to gather insights and discusses implementation, value and technologies.
This collaborative webinar discusses available postgraduate courses and insights from alumni into how their qualification helped advance their understanding of pharmaceutical medicine and their career.
At the conclusion of this session, participants should better understand digital trends seen within Medical Affairs today as well as be aware of why HCP expectations are changing and how to evolve with them to provide better customer experiences
Evaluate the commonalities and differences in the use, structure and evolution of scientific communications platforms within and between companies; understand how a HealthScience approach can help to integrate insights, communications and evidence generation plans across multiple functions
This MAPS podcast introduces listeners to social listening to gather insights and discusses implementation, value and technologies.
This Webinar provides perspectives on the evolving role of Digital Opinion Leaders in medical education and shares approaches for identifying, monitoring and engaging them in a compliant manor with relevant examples.
Part 2 of this series will discuss statistical analysis in clinical trials including null/alternative hypotheses; statistical assumptions (type I error, significance level, type II error, statistical power); hypothesis testing; Statistics used in RCTs, including type of outcome measures, analysis of time-to-event variables (plotting and interpretation of Kaplan-Meier curves).
Early Access includes a variety of programs by which pharmaceutical companies make investigational therapies available to patients with life-threatening diseases. These patients have either exhausted available treatments or have no approved options. This presentation will review the processes and procedures to consider in the implementation of an Early Access Program and explore the opportunities and challenges posed therein.